about
A Blueprint for HIV Vaccine DiscoveryUsing epigenetics to define vaccine-induced memory T cellsA global approach to HIV-1 vaccine developmentConsensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cellsA vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II moleculesDefining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateT-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizationsEarly potent protection against heterologous SIVsmE660 challenge following live attenuated SIV vaccination in Mauritian cynomolgus macaques.Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infectionsTemporal expression of bacterial proteins instructs host CD4 T cell expansion and Th17 development.New approaches to design HIV-1 T-cell vaccinesOverview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineLimited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyDissecting the dynamics of HIV-1 protein sequence diversity.Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.Coordinate linkage of HIV evolution reveals regions of immunological vulnerability.Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes.Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infectionTreatment as prevention: preparing the wayHow can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccineA Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein BoostImmune-mediated attenuation of HIV-1Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.Enhanced Recognition of HIV-1 Cryptic Epitopes Restricted by HLA Class I Alleles Associated With a Favorable Clinical Outcome.Antiretroviral drugs: critical issues and recent advancesA Novel Codon-optimized SIV Gag-pol Immunogen for Gene-based VaccinationGood CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccinesCharacterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesA Recombinant Adenovirus Encoding Multiple HIV-1 Epitopes Induces Stronger CD4(+) T cell Responses than a DNA Vaccine in Mice.Polyvalent AIDS vaccines.Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).Achieving a cure for HIV infection: do we have reasons to be optimistic?Animal models in virus research: their utility and limitations.
P2860
Q26829865-670FD568-2C6C-45FA-BE1D-F0384BC68B6EQ26849423-1DE89310-0921-472E-AFA0-3D9B2BEA8571Q27024614-E6B43339-9CA9-415F-A501-A50231C9EB34Q28487823-F364E6A2-5C9E-43DD-8EF6-B74D3BF817A5Q28751663-C274EDB3-2B7D-42B2-984A-448C8AA8AECEQ30410411-7805BF3D-1DC0-4B90-A4A1-AD47F50E187CQ33749950-543FCE32-E1E6-444E-BFB7-2F17712E857BQ33833624-68C68B0B-8DA2-4C21-8B1B-702A98CF8F13Q33996900-5D9EEDD2-529D-498F-B19A-A7450C935269Q34042642-5F5E5583-332C-4CCD-8130-B6FDA2387C8AQ34139977-41C0A2A8-D425-4236-9F38-6588315571C8Q34274849-C078199D-F672-4D50-A136-864E6438BE5EQ34373275-B15F5250-4068-4EC8-8F23-4B2F99E8DD3FQ34630446-31FB12EA-DCA9-4C62-985D-471C19312627Q34672589-B0106AB9-4EF3-4383-B7A4-28C393C49FF5Q34741882-CBB6B319-376D-4CE0-9C16-CD8A6E2A7387Q34834065-AC0D88C1-58E7-4AC6-B9F6-08D3BC7436BFQ35105172-6C2FE38A-5727-4258-90AB-443B481E3E01Q35244904-CB2E70CA-5350-4539-BB7E-799D8EA5E443Q35274776-A4EE9C8C-2D70-4130-A2CB-CDB3DF54C7AEQ35357663-1548977D-4BFE-4882-93B0-0B7A6BA6DA1CQ35653703-76D3C785-0000-429D-B019-16CA2869B867Q35709133-25111168-2788-4D2A-A381-0091419AC882Q35757125-530906E4-2D77-4895-A411-CE0BD71AD088Q35760486-C6E7D567-951D-4BA4-8E35-79B208302E66Q35798108-18270D10-451B-4E59-B3CA-DE3FD6CC9912Q35826171-E645D168-08EB-4A47-9C26-4A111F951799Q36001347-4BAD2971-5E70-43E4-A15D-D9186B75F433Q36015624-DE752D8B-D747-4B2A-9C69-CBAFD6313AD2Q36020992-606B94F8-B6B7-479B-8373-6DFF0AB7A4B4Q36248077-CC0E11D3-5858-4F68-B3B6-B698FC0D423DQ36356350-24A1630F-D6A2-4C38-A895-F36007D20A6CQ36495587-DF44D976-EE76-4F71-BFC5-305AF5B63E90Q36593175-99219B16-4B2F-4294-A85F-1B23155F487FQ36956883-6668BC73-63DB-4F19-B2A7-12FBBBE442AEQ37094429-07A53FF5-9EB5-4ACE-805C-F28B86F2FCC8Q37560829-277C4C76-2A21-47F5-8131-7FEB5E8290B2Q37967232-C76E1707-2BD3-4180-9C6A-9C33D4F1D72DQ37980423-69A177D3-8BC9-47DD-9D8E-E9E6239949E0Q38043556-528AB9C6-89C4-4577-977D-62DC268A3B9F
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
HIV-1 vaccine development after STEP.
@ast
HIV-1 vaccine development after STEP.
@en
type
label
HIV-1 vaccine development after STEP.
@ast
HIV-1 vaccine development after STEP.
@en
prefLabel
HIV-1 vaccine development after STEP.
@ast
HIV-1 vaccine development after STEP.
@en
P2860
P1476
HIV-1 vaccine development after STEP.
@en
P2860
P304
P356
10.1146/ANNUREV.MED.042508.093728
P577
2010-01-01T00:00:00Z